The locus coeruleus (LC) is one of the earliest brain regions to accumulate hyperphosphorylated tau, but a lack of animal models that recapitulate this pathology has hampered our understanding of its contributions to Alzheimer’s disease (AD) pathophysiology.
Objective:
We previously reported that TgF344-AD rats, which overexpress mutant human amyloid precursor protein and presenilin-1, accumulate early endogenous hyperphosphorylated tau in the LC. Here, we used TgF344-AD rats and a wild-type (WT) human tau virus to interrogate the effects of endogenous hyperphosphorylated rat tau and human tau in the LC on AD-related neuropathology and behavior.
Methods:
Two-month-old TgF344-AD and WT rats received bilateral LC infusions of full-length WT human tau or mCherry control virus driven by the noradrenergic-specific PRSx8 promoter. Rats were subsequently assessed at 6 and 12 months for arousal (sleep latency), anxiety-like behavior (open field, elevated plus maze, novelty-suppressed feeding), passive coping (forced swim task), and learning and memory (Morris water maze and fear conditioning). Hippocampal microglia, astrocyte, and AD pathology were evaluated using immunohistochemistry.
Results:
In general, the effects of age were more pronounced than genotype or treatment; older rats displayed greater hippocampal pathology, took longer to fall asleep, had reduced locomotor activity, floated more, and had impaired cognition compared to younger animals. TgF344-AD rats showed increased anxiety-like behavior and impaired learning and memory. The tau virus had negligible influence on most measures.
Conclusion:
Effects of hyperphosphorylated tau on AD-like neuropathology and behavioral symptoms were subtle. Further investigation of different forms of tau is warranted.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
6.
CaspersenC, WangN, YaoJ, SosunovA, ChenX, LustbaderJW, XuHW, SternD, McKhannG, YanSD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J19, 2040–2041.
7.
MaoP, ReddyPH (2011) Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: Implications for early intervention and therapeutics. Biochim Biophys Acta1812, 1359–1370.
8.
LeunerK, MullerWE, ReichertAS (2012) From mitochondrial dysfunction to amyloid beta formation: Novel insights into the pathogenesis of Alzheimer’s disease. Mol Neurobiol46, 186–193.
9.
ChauhanV, ChauhanA (2006) Oxidative stress in Alzheimer’s disease. Pathophysiology13, 195–208.
10.
LaurenJ, GimbelDA, NygaardHB, GilbertJW, StrittmatterSM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature457, 1128–1132.
LacorPN, BunielMC, FurlowPW, ClementeAS, VelascoPT, WoodM, ViolaKL, KleinWL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci27, 796–807.
13.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42, 631–639.
14.
FaganAM, RoeCM, XiongC, MintunMA, MorrisJC, HoltzmanDM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol64, 343–349.
15.
Gomez-IslaT, HollisterR, WestH, MuiS, GrowdonJH, PetersenRC, ParisiJE, HymanBT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol41, 17–24.
16.
BraakH, ThalDR, GhebremedhinE, Del TrediciK (2011) Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol70, 960–969.
17.
PletnikovaO, KageyamaY, RudowG, LaClairKD, AlbertM, CrainBJ, TianJ, FowlerD, TroncosoJC (2018) The spectrum of preclinical Alzheimer’s disease pathology and its modulation by ApoE genotype. Neurobiol Aging71, 72–80.
18.
TheofilasP, EhrenbergAJ, DunlopS, Di Lorenzo AlhoAT, NguyA, LeiteREP, RodriguezRD, MejiaMB, SuemotoCK, Ferretti-RebustiniREL, PolichisoL, NascimentoCF, SeeleyWW, NitriniR, PasqualucciCA, Jacob FilhoW, RuebU, NeuhausJ, HeinsenH, GrinbergLT (2017) Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement13, 236–246.
19.
PoeGR, FooteS, EschenkoO, JohansenJP, BouretS, Aston-JonesG, HarleyCW, Manahan-VaughanD, WeinshenkerD, ValentinoR, BerridgeC, ChandlerDJ, WaterhouseB, SaraSJ (2020) Locus coeruleus: A new look at the blue spot. Nat Rev Neurosci21, 644–659.
20.
ChandlerDJ, JensenP, McCallJG, PickeringAE, SchwarzLA, TotahNK (2019) Redefining noradrenergic neuromodulation of behavior: Impacts of a modular locus coeruleus architecture. J Neurosci39, 8239–8249.
21.
SaraSJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci10, 211–223.
22.
Aston-JonesG, CohenJD (2005) An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annu Rev Neurosci28, 403–450.
23.
HamannSB, MonarchES, GoldsteinFC (2000) Memory enhancement for emotional stimuli is impaired in early Alzheimer’s disease. Neuropsychology14, 82–92.
Winsky-SommererR, de OliveiraP, LoomisS, WaffordK, DijkDJ, GilmourG (2019) Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: Insights from studies in patient populations and animal models. Neurosci Biobehav Rev97, 112–137.
26.
YesavageJA, FriedmanL, KraemerH, TinklenbergJR, SalehiA, NodaA, TaylorJL, O’HaraR, MurphyG (2004) Sleep/wake disruption in Alzheimer’s disease: APOE status and longitudinal course. J Geriatr Psychiatry Neurol17, 20–24.
27.
BerardiAM, ParasuramanR, HaxbyJV (2005) Sustained attention in mild Alzheimer’s disease. Dev Neuropsychol28, 507–537.
28.
PietrzakRH, LimYY, NeumeisterA, AmesD, EllisKA, HarringtonK, LautenschlagerNT, RestrepoC, MartinsRN, MastersCL, VillemagneVL, RoweCC, MaruffP, Australian ImagingB, Lifestyle ResearchG (2015) Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. JAMA Psychiatry72, 284–291.
29.
TeriL, FerrettiLE, GibbonsLE, LogsdonRG, McCurrySM, KukullWA, McCormickWC, BowenJD, LarsonEB (1999) Anxiety of Alzheimer’s disease: Prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci54, M348–352.
30.
GendronTF, PetrucelliL (2009) The role of tau in neurodegeneration. Mol Neurodegener4, 13.
31.
WittmannCW, WszolekMF, ShulmanJM, SalvaterraPM, LewisJ, HuttonM, FeanyMB (2001) Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science293, 711–714.
32.
GhoshA, TorravilleSE, MukherjeeB, WallingSG, MartinGM, HarleyCW, YuanQ (2019) An experimental model of Braak’s pretangle proposal for the origin of Alzheimer’s disease: The role of locus coeruleus in early symptom development. Alzheimers Res Ther11, 59.
33.
ArendtT, BrucknerMK, MorawskiM, JagerC, GertzHJ (2015) Early neurone loss in Alzheimer’s disease: Cortical or subcortical?Acta Neuropathol Commun3, 10.
34.
BuschC, BohlJ, OhmTG (1997) Spatial, temporal and numeric analysis of Alzheimer changes in the nucleus coeruleus. Neurobiol Aging18, 401–406.
35.
EhrenbergAJ, SuemotoCK, Franca ResendeEP, PetersenC, LeiteREP, RodriguezRD, Ferretti-RebustiniREL, YouM, OhJ, NitriniR, PasqualucciCA, Jacob-FilhoW, KramerJH, GatchelJR, GrinbergLT (2018) Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis66, 115–126.
36.
MatchettBJ, GrinbergLT, TheofilasP, MurrayME (2021) The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer’s disease. Acta Neuropathol141, 631–650.
37.
ShibataE, SasakiM, TohyamaK, OtsukaK, EndohJ, TerayamaY, SakaiA (2008) Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol Psychiatry64, 401–406.
38.
ShibataE, SasakiM, TohyamaK, OtsukaK, SakaiA (2007) Reduced signal of locus ceruleus in depression in quantitative neuromelanin magnetic resonance imaging. Neuroreport18, 415–418.
39.
KnudsenK, FedorovaTD, HansenAK, SommerauerM, OttoM, SvendsenKB, NahimiA, StokholmMG, PaveseN, BeierCP, BrooksDJ, BorghammerP (2018) In-vivo staging of pathology in REM sleep behaviour disorder: A multimodality imaging case-control study. Lancet Neurol17, 618–628.
40.
EhrmingerM, LatimierA, PyatigorskayaN, Garcia-LorenzoD, Leu-SemenescuS, VidailhetM, LehericyS, ArnulfI (2016) The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain139, 1180–1188.
41.
OlivieriP, LagardeJ, LehericyS, ValabregueR, MichelA, MaceP, CailleF, GervaisP, BottlaenderM, SarazinM (2019) Early alteration of the locus coeruleus in phenotypic variants of Alzheimer’s disease. Ann Clin Transl Neurol6, 1345–1351.
42.
WilsonRS, NagS, BoylePA, HizelLP, YuL, BuchmanAS, SchneiderJA, BennettDA (2013) Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology80, 1202–1208.
43.
KellySC, HeB, PerezSE, GinsbergSD, MufsonEJ, CountsSE (2017) Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol Commun5, 8.
44.
JacobsHIL, Muller-EhrenbergL, PriovoulosN, RoebroeckA (2018) Curvilinear locus coeruleus functional connectivity trajectories over the adult lifespan: A 7T MRI study. Neurobiol Aging69, 167–176.
45.
JacobsHI, PriovoulosN, PoserBA, PagenLH, IvanovD, VerheyFR, UludagK (2020) Dynamic behavior of the locus coeruleus during arousal-related memory processing in a multi-modal 7T fMRI paradigm. Elife9, e52059.
46.
JacobsHI, WieseS, van de VenV, GronenschildEH, VerheyFR, MatthewsPM (2015) Relevance of parahippocampal-locus coeruleus connectivity to memory in early dementia. Neurobiol Aging36, 618–626.
47.
Del CerroI, Martinez-ZalacainI, Guinea-IzquierdoA, Gascon-BayarriJ, Vinas-DiezV, UrretavizcayaM, Naval-BaudinP, AguileraC, Rene-RamirezR, FerrerI, MenchonJM, SoriaV, Soriano-MasC (2020) Locus coeruleusconnectivity alterations in late-life major depressive disorder during a visual oddball task. Neuroimage Clin28, 102482.
48.
GrueschowM, StenzN, ThornH, EhlertU, BreckwoldtJ, Brodmann MaederM, ExadaktylosAK, BingisserR, RuffCC, KleimB (2021) Real-world stress resilience is associated with the responsivity of the locus coeruleus. Nat Commun12, 2275.
49.
ZhaoS, RangaprakashD, VenkataramanA, LiangP, DeshpandeG (2017) Investigating focal connectivity deficits in Alzheimer’s disease using directional brain networks derived from resting-state fMRI. Front Aging Neurosci9, 211.
50.
JohanssonM, StomrudE, InselPS, LeuzyA, JohanssonPM, SmithR, IsmailZ, JanelidzeS, PalmqvistS, van WestenD, Mattsson-CarlgrenN, HanssonO (2021) Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease. Transl Psychiatry11, 76.
51.
BabulalGM, RoeCM, StoutSH, RajasekarG, WischJK, BenzingerTLS, MorrisJC, AncesBM (2020) Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults. J Alzheimers Dis74, 1045–1055.
52.
Pichet BinetteA, Vachon-PresseauÉ, MorrisJ, BatemanR, BenzingerT, CollinsDL, PoirierJ, BreitnerJCS, VilleneuveS; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group (2021) Amyloid and taupathology associations with personality traits, neuropsychiatric symptoms, and cognitive lifestyle in thepreclinical phases of sporadic and autosomal dominant Alzheimer’s disease. Biol Psychiatry89, 776–785.
53.
d’Oleire UquillasF, JacobsHIL, BiddleKD, ProperziM, HanseeuwB, SchultzAP, RentzDM, JohnsonKA, SperlingRA, DonovanNJ (2018) Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry8, 282.
54.
GatchelJR, DonovanNJ, LocascioJJ, SchultzAP, BeckerJA, ChhatwalJ, PappKV, AmariglioRE, RentzDM, BlackerD, SperlingRA, JohnsonKA, MarshallGA (2017) Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: A pilot study. J Alzheimers Dis59, 975–985.
55.
KelbermanM, KeilholzS, WeinshenkerD (2020) What’s that (blue) spot on my MRI? Multimodal neuroimaging of the locus coeruleus in neurodegenerative disease. Front Neurosci14, 583421.
56.
ChalermpalanupapT, SchroederJP, RorabaughJM, LilesLC, LahJJ, LeveyAI, WeinshenkerD (2018) Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. J Neurosci38, 74–92.
57.
HenekaMT, RamanathanM, JacobsAH, Dumitrescu-OzimekL, Bilkei-GorzoA, DebeirT, SastreM, GalldiksN, ZimmerA, HoehnM, HeissWD, KlockgetherT, StaufenbielM (2006) Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci26, 1343–1354.
58.
Jardanhazi-KurutzD, KummerMP, TerwelD, VogelK, DyrksT, ThieleA, HenekaMT (2010) Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int57, 375–382.
59.
CaoS, FisherDW, RodriguezG, YuT, DongH (2021) Comparisons of neuroinflammation, microglial activation, and degeneration of the locus coeruleus-norepinephrine system in APP/PS1 and aging mice. J Neuroinflammation18, 10.
60.
MehlaJ, LacoursiereSG, LapointeV, McNaughtonBL, SutherlandRJ, McDonaldRJ, MohajeraniMH (2019) Age-dependent behavioral and biochemical characterization of single APP knock-in mouse (APP(NL-G-F/NL-G-F)) model of Alzheimer’s disease. Neurobiol Aging75, 25–37.
61.
O’NeilJN, MoutonPR, TizabiY, OttingerMA, LeiDL, IngramDK, ManayeKF (2007) Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat34, 102–107.
62.
LiuY, YooMJ, SavonenkoA, StirlingW, PriceDL, BorcheltDR, MamounasL, LyonsWE, BlueME, LeeMK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model ofAlzheimer’s disease. J Neurosci28, 13805–13814.
63.
RorabaughJM, ChalermpalanupapT, Botz-ZappCA, FuVM, LembeckNA, CohenRM, WeinshenkerD (2017) Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease. Brain140, 3023–3038.
64.
YoshiyamaY, HiguchiM, ZhangB, HuangSM, IwataN, SaidoTC, MaedaJ, SuharaT, TrojanowskiJQ, LeeVM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron53, 337–351.
65.
KangSS, LiuX, AhnEH, XiangJ, ManfredssonFP, YangX, LuoHR, LilesLC, WeinshenkerD, YeK (2020) Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. J Clin Invest130, 422–437.
66.
CohenRM, Rezai-ZadehK, WeitzTM, RentsendorjA, GateD, SpivakI, BholatY, VasilevkoV, GlabeCG, BreunigJJ, RakicP, DavtyanH, AgadjanyanMG, KepeV, BarrioJR, BannykhS, SzekelyCA, PechnickRN, TownT (2013) A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci33, 6245–6256.
67.
SareRM, CookeSK, KrychL, ZerfasPM, CohenRM, SmithCB (2020) Behavioral phenotype in the TgF344-AD rat modelof Alzheimer’s disease. Front Neurosci14, 601.
68.
Munoz-MorenoE, TudelaR, Lopez-GilX, SoriaG (2018) Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer’s disease. Alzheimers Res Ther10, 16.
69.
PentkowskiNS, BerkowitzLE, ThompsonSM, DrakeEN, OlguinCR, ClarkBJ (2018) Anxiety-like behavior as an early endophenotype in the TgF344-AD rat model of Alzheimer’s disease. Neurobiol Aging61, 169–176.
70.
HwangDY, CarlezonWAJr., IsacsonO, KimKS (2001) A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum Gene Ther12, 1731–1740.
71.
HunsleyMS, PalmiterRD (2004) Altered sleep latency and arousal regulation in mice lacking norepinephrine. Pharmacol Biochem Behav78, 765–773.
72.
Porter-StranskyKA, CentanniSW, KarneSL, OdilLM, FekirS, WongJC, JeromeC, MitchellHA, EscaygA, PedersenNP, WinderDG, MitranoDA, WeinshenkerD (2019) Noradrenergic transmission at alpha1-adrenergic receptors in the ventral periaqueductal gray modulates arousal. Biol Psychiatry85, 237–247.
73.
FriardO, GambaM (2016) BORIS: A free, versatile open-source event-logging software for video/audio coding and live observations. Br Ecol Soc7, 1325–1330.
74.
SathyanesanA, OguraT, LinW (2012) Automated measurement of nerve fiber density using line intensity scan analysis. J Neurosci Methods206, 165–175.
75.
McCallJG, Al-HasaniR, SiudaER, HongDY, NorrisAJ, FordCP, BruchasMR (2015) CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron87, 605–620.
76.
CurtisAL, LechnerSM, PavcovichLA, ValentinoRJ (1997) Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: Effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J Pharmacol Exp Ther281, 163–172.
77.
CurtisAL, LeiserSC, SnyderK, ValentinoRJ (2012) Predator stress engages corticotropin-releasing factor and opioid systems to alter the operating mode of locus coeruleus norepinephrine neurons. Neuropharmacology62, 1737–1745.
78.
PageME, AbercrombieED (1999) Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse33, 304–313.
79.
ValentinoRJ, FooteSL (1988) Corticotropin-releasing hormone increases tonic but not sensory-evoked activity of noradrenergic locus coeruleus neurons in unanesthetized rats. J Neurosci8, 1016–1025.
80.
PentkowskiNS, Rogge-ObandoKK, DonaldsonTN, BouquinSJ, ClarkBJ (2021) Anxiety and Alzheimer’s disease: Behavioral analysis and neural basis in rodent models of Alzheimer’s-related neuropathology. Neurosci Biobehav Rev127, 647–658.
81.
DulawaSC, HenR (2005) Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test. Neurosci Biobehav Rev29, 771–783.
82.
LustbergD, TillageRP, BaiY, PruittM, LilesLC, WeinshenkerD (2020) Noradrenergic circuits in the forebrain control affective responses to novelty. Psychopharmacology (Berl)237, 3337–3355.
83.
CommonsKG, CholaniansAB, BabbJA, EhlingerDG (2017) The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem Neurosci8, 955–960.
84.
de KloetER, MolendijkML (2016) Coping with the forced swim stressor: Towards understanding an adaptive mechanism. Neural Plast2016, 6503162.
85.
GoodmanAM, LangnerBM, JacksonN, AlexC, McMahonLL (2021) Heightened hippocampal beta-adrenergic receptor function drives synaptic potentiation and supports learning and memory in the TgF344-AD rat model during prodromal Alzheimer’s disease. J Neurosci41, 5747–5761.
86.
KreuzerM, KeatingGL, FenzlT, HartnerL, SinonCG, HajjarI, CiavattaV, RyeDB, GarciaPS (2020) Sleep/wake behavior and EEG signatures of the TgF344-AD rat model at the prodromal stage. Int J Mol Sci21, 9290.
87.
ButkovichLM, HouserMC, ChalermpalanupapT, Porter-StranskyKA, IannitelliAF, BolesJS, LloydGM, CoomesAS, EidsonLN, De Sousa RodriguesME, OliverDL, KellySD, ChangJ, Bengoa-VergnioryN, Wade-MartinsR, GiassonBI, JoersV, WeinshenkerD, TanseyMG (2020) Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus ceruleus pathology and nonmotor features of Parkinson’s disease. J Neurosci40, 7559–7576.
88.
ScattoniML, GaspariniL, AllevaE, GoedertM, CalamandreiG, SpillantiniMG (2010) Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res208, 250–257.
89.
WangX, SmithK, PearsonM, HughesA, CosdenML, MarcusJ, HessJF, SavageMJ, RosahlT, SmithSM, SchachterJB, UslanerJM (2018) Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. PLoS One13, e0195486.
90.
JulP, VolbrachtC, de JongIE, HelboeL, ElvangAB, PedersenJT (2016) Hyperactivity with agitative-likebehavior in a mouse tauopathy model. J Alzheimers Dis49, 783–795.
91.
BeckerE, Orellana RiosCL, LahmannC, RuckerG, BauerJ, BoekerM (2018) Anxiety as a risk factor of Alzheimer’sdisease and vascular dementia. Br J Psychiatry213, 654–660.
92.
RasmussenH, RosnessTA, BosnesO, SalvesenØ, KnutliM, StordalE (2018) Anxiety and depression as risk factors in frontotemporal dementia and Alzheimer’s disease: The HUNT Study. Dement Geriatr Cogn Disord Extra8, 414–425.
93.
WuC, YangL, LiY, DongY, YangB, TuckerLD, ZongX, ZhangQ (2020) Effects of exercise training on anxious-depressive-like behavior in Alzheimer rat. Med Sci Sports Exerc52, 1456–1469.
94.
BogdanovaOV, KanekarS, D’AnciKE, RenshawPF (2013) Factors influencing behavior in the forced swim test. Physiol Behav118, 227–239.
95.
SzotP, WhiteSS, GreenupJL, LeverenzJB, PeskindER, RaskindMA (2006) Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci26, 467–478.
96.
SzotP, WhiteSS, GreenupJL, LeverenzJB, PeskindER, RaskindMA (2007) Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: Evidence of compensatory changes. Neuroscience146, 471–480.
97.
BuscheMA, HymanBT (2020) Synergy between amyloid-beta and tau in Alzheimer’s disease. Nat Neurosci23, 1183–1193.
98.
CriminsJL, RocherAB, LuebkeJI (2012) Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol124, 777–795.
99.
HolthJK, BombenVC, ReedJG, InoueT, YounkinL, YounkinSG, PautlerRG, BotasJ, NoebelsJL (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci33, 1651–1659.
100.
HuijbersW, SchultzAP, PappKV, LaPointMR, HanseeuwB, ChhatwalJP, HeddenT, JohnsonKA, SperlingRA (2019) Tau accumulation in clinically normal older adults is associated with hippocampal hyperactivity. J Neurosci39, 548–556.
KellyL, SeifiM, MaR, MitchellSJ, RudolphU, ViolaKL, KleinWL, LambertJJ, SwinnyJD (2021) Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer’s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathol Appl Neurobiol47, 488–505.
103.
VankovA, Herve-MinvielleA, SaraSJ (1995) Response to novelty and its rapid habituation in locus coeruleus neurons of the freely exploring rat. Eur J Neurosci7, 1180–1187.
104.
Herve-MinvielleA, SaraSJ (1995) Rapid habituation of auditory responses of locus coeruleus cells in anaesthetized and awake rats. Neuroreport6, 1363–1368.
FritschT, SmythKA, DebanneSM, PetotGJ, FriedlandRP (2005) Participation in novelty-seeking leisure activities and Alzheimer’s disease. J Geriatr Psychiatry Neurol18, 134–141.
108.
WeinshenkerD (2018) Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci41, 211–223.
109.
HagenaH, HansenN, Manahan-VaughanD (2016) beta-adrenergic control of hippocampal function: Subserving the choreography of synaptic information storage and memory. Cereb Cortex26, 1349–1364.
110.
HansenN, Manahan-VaughanD (2015) Locus coeruleus stimulation facilitates long-term depression in the dentate gyrus that requires activation of beta-adrenergic receptors. Cereb Cortex25, 1889–1896.
111.
GiustinoTF, MarenS (2018) Noradrenergic modulation of fear conditioning and extinction. Front Behav Neurosci12, 43.
RittenhousePA, Lopez-RubalcavaC, StanwoodGD, LuckiI (2002) Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology27, 303–318.
114.
TillageRP, SciolinoNR, PlummerNW, LustbergD, LilesLC, HsiangM, PowellJM, SmithKG, JensenP, WeinshenkerD (2020) Elimination of galanin synthesis in noradrenergic neurons reduces galanin in select brain areas and promotes active coping behaviors. Brain Struct Funct225, 785–803.
115.
HoletsVR, HokfeltT, RokaeusA, TereniusL, GoldsteinM (1988) Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience24, 893–906.
116.
MillerMA, KolbPE, LeverenzJB, PeskindER, RaskindMA (1999) Preservation of noradrenergic neurons in the locus ceruleus that coexpress galanin mRNA in Alzheimer’s disease. J Neurochem73, 2028–2036.
117.
OlpeHR, SteinmannMW (1982) Age-related decline in the activity of noradrenergic neurons of the rat locus coeruleus. Brain Res251, 174–176.
118.
PeskindER, TsuangDW, BonnerLT, PascualyM, RiekseRG, SnowdenMB, ThomasR, RaskindMA (2005) Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study. Alzheimer Dis Assoc Disord19, 23–28.
119.
WangLY, ShoferJB, RohdeK, HartKL, HoffDJ, McFallYH, RaskindMA, PeskindER (2009) Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry17, 744–751.
120.
LeveyAI, QiuD, ZhaoL, HuWT, DuongDM, HigginbothamL, DammerEB, SeyfriedNT, WingoTS, HalesCM, Gamez TanseyM, GoldsteinDS, AbrolA, CalhounVD, GoldsteinFC, HajjarI, FaganAM, GalaskoD, EdlandSD, HanfeltJ, LahJJ, WeinshenkerD (2021) A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain, doi:10.1093/brain/awab452.
